1.	ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and older Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00032, 6474IL/0032, NCT00312377
2.	Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351
3.	ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00044, EUDRACT Number 2006-002384-12, NCT00404924
4.	Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00036, EUDRACT No. 2006-003695-35, NCT00418886
5.	Phase I/II Randomized Study of Vandetanib, Oxaliplatin, and Docetaxel in Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CASE-6507, CASE6507, SANOFI-AVENTIS-CASE-6507, NCT00732745
6.	Phase II Study of ZD6474 in Patients With Relapsed Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-IND145, ZENECA-6474IL/0004, IND145
7.	Phase II Randomized Study of ZD6474 and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to Platinum-Based Chemotherapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0208009, ZENECA-6474IL/0006, NCT00054093
8.	Phase II Randomized Study of ZD6474 in Patients With Small Cell Lung Cancer Who Responded to Induction Chemotherapy With or Without Radiotherapy Phase: Phase II Type: Treatment Status: Closed Age: Over 16 Sponsor: Other Protocol IDs: CAN-NCIC-BR20, ZENECA-6474IL/0005, NCT00066313, BR20
9.	Phase II Randomized Study of ZD6474 Versus Gefitinib (ZD1839) in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Who Failed Prior First-Line Platinum-Based Chemotherapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-03090, ZENECA-6474IL/0003, NCT00059722
10.	Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00008, NCT00098345
11.	A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00068, NCT00358956
12.	An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00058, NCT00410761
13.	Phase II Study of Vandetanib in Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-07-C-0061, NCI-P7041, NCT00445549
14.	Phase II Study of Neoadjuvant Vandetanib in Combination With Carboplatin and Paclitaxel in Patients With Resectable Stage IB, II, or IIIA Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: WSU-2006-122, WSU 2006-122, WSU-011807MP2F, WSU-0612004427, ZENECA-IRUSZACT0029, NCT00459121
15.	A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00048, NCT00454116
16.	A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00047, NCT00500292
17.	Phase II Study of Best Support Care (BSC) Plus ZD6474 in Patients With Inoperable Hepatocellular Carcinoma (HCC) Phase: Phase II Type: Treatment Status: Closed Age: 20 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00072, NCT00508001
18.	Efficacy and Safety of Zactima™ in Patients With Metastatic Papillary or Follicular Thyroid Cancer Phase: Phase II Type: Tissue collection/Repository, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00079, NCT00537095
19.	ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 06-402, NCT00496665
20.	Phase I Chinese PK Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200L00004, NCT00503711
21.	Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00085, EUDRACT Number 2008-005556-24, NCT00807170